Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Trava Health

Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Trava Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 134 · Grade C

Trava Health

Visit Trava Health Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 70 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

That doesn't make Trava Health a bad call — it's best for readers who want cash-sensitive patients comfortable with multi-pharmacy 503a sourcing without legitscript verification. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
48
Supply Reliability
95
66
Transparency
90
88
Access Breadth
93
90
Clinical Oversight
92
69
Track Record
88
68
CoreAge RxBrief Score 94 · 70Trava Health

Price, coverage & the tracker

CoreAge RxTrava Health
Brief Score94/100 (A)70/100 (C)
Semaglutide$149/moFrom $119/mo (starting dose, compounded)
Tirzepatide$349/moFrom $198/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.

Trava Health: New to the tracker on 1 August 2026. The published line reads From $119/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.